drugset / Trial / NCT03638817

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

NCT03638817

NaSingle-groupOpen-labelTreatment

Summary

The objective of the study is to estimate the response to eltrombopag based on platelet count increase above a safety level of 80 G/L and lack of requirement for pre-, per- and post-operative administration of platelet concentrates (PC) for performing elective invasive acts at mild or high bleeding risk,in selected patients with inherited thrombocytopenia (IT).

Timeline

Start
2019-08-02
Primary completion
2023-06-27
Completion
2023-06-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 25 mg Oral
Subject Eltrombopag Small molecule 50 mg Oral
Subject Eltrombopag Small molecule 75 mg Oral